Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
Verona Pharma plc (VRP.L) Phase 3 Clinical Trials with Nebulized Ensifentrine
Share Talk Bulletin Board Heroes, Friday 14th August 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Share Talk Weekly Stock Market News, 19th July 2020
Share Talk highlighted nine, yes nine new company “52-wk high” across our social media platforms, who said private/retail investors do not like the small micro-cap space.
Verona Pharma plc (VRP.L) $200 Million in Oversubscribed Private Placement and Subscription
Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has raised approximately $200 million (£159 million*).
Share Talk Bulletin Board Heroes, Tuesday 31st March 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Exclusive to Share Talk, here
Verona Pharma plc (LON:VRP) Positive Top-line Data in 4 Week Phase 2b COPD Study.
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function
Share Talk Bulletin Board Heroes, Tuesday 7th January 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Monday, 5th August 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
